Ventripoint Diagnostics Ltd (OTCMKTS:VPTDF) Stock Surges 25% In a Week: But Why?

On Tuesday Ventripoint Diagnostics Ltd (OTCMKTS:VPTDF) made a momentous new announcement with regards to the fact that it had been successful in getting the certification for its cardiac diagnostic system from the European Union Medical Device Regulation. It was a significant milestone for the company and further reinforced its commitment to providing advanced diagnostic tools to healthcare professionals so as to improve patient outcomes.

Trading Data

On Tuesday, VPTDF stock gained 1.28% to $0.1500 with more than 3.70K shares, compared to its average volume of 43.98K shares. The stock moved within a range of $0.1500 – 0.1539 after opening trade at $0.1539.

Ventripoint Receives European Union Medical Device Regulation Certification

The certification actually came into effect back in May 2021 and all medical devices which are certified with the Medical Device Directive in the European Union must also get the EU MDR certification. Only if that certification is obtained could a company sell the concerned medical device in the European Market.

The receipt of the EU MDR certification was important for the company for another reason too. It indicated the fact that Ventripoint Diagnostics had the ability to keep pace with the latest regulatory developments and provide a safe cardiac diagnostic tool that could be sold in the European market.

The company is currently working on further boosting its presence in the lucrative European market and change the way in which cardiac diseases are treated and diagnosed.